Monte Rosa Therapeutics, Inc.
GLUE
$3.70
-$0.34-8.42%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 84.93M | 60.65M | 9.22M | 4.70M | 1.06M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 84.93M | 60.65M | 9.22M | 4.70M | 1.06M |
| Cost of Revenue | -- | 36.76M | 25.52M | -- | -- |
| Gross Profit | 84.93M | 23.89M | -16.30M | 4.70M | 1.06M |
| SG&A Expenses | 10.78M | 10.88M | 10.23M | 9.28M | 11.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.89M | 47.64M | 35.74M | 37.34M | 36.01M |
| Operating Income | 44.04M | 13.00M | -26.53M | -32.64M | -34.95M |
| Income Before Tax | 47.71M | 15.60M | -23.79M | -30.06M | -31.89M |
| Income Tax Expenses | 822.00K | 2.16M | 71.00K | 252.00K | 83.00K |
| Earnings from Continuing Operations | 46.89M | 13.44M | -23.86M | -30.31M | -31.97M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 46.89M | 13.44M | -23.86M | -30.31M | -31.97M |
| EBIT | 44.04M | 13.00M | -26.53M | -32.64M | -34.95M |
| EBITDA | 46.08M | 15.07M | -24.42M | -30.58M | -33.05M |
| EPS Basic | 0.57 | 0.16 | -0.29 | -0.43 | -0.53 |
| Normalized Basic EPS | 0.36 | 0.12 | -0.18 | -0.26 | -0.33 |
| EPS Diluted | 0.57 | 0.16 | -0.29 | -0.43 | -0.53 |
| Normalized Diluted EPS | 0.36 | 0.12 | -0.18 | -0.26 | -0.33 |
| Average Basic Shares Outstanding | 82.15M | 82.12M | 82.01M | 71.23M | 60.16M |
| Average Diluted Shares Outstanding | 82.96M | 82.12M | 82.01M | 71.23M | 60.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |